+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Long-acting Somatostatin Analogues Market - Global Forecast 2025-2030- Product Image
Long-acting Somatostatin Analogues Market - Global Forecast 2025-2030- Product Image
Sale

Long-acting Somatostatin Analogues Market - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 182 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6117597
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Long-acting somatostatin analogues are redefining therapeutic strategies for managing complex endocrine disorders, providing sustained hormone suppression and fostering significant improvements in patient adherence, clinical outcomes, and healthcare efficiencies.

Market Snapshot: Long-acting Somatostatin Analogues

The market for long-acting somatostatin analogues is experiencing substantial growth, supported by the clinical need for chronic endocrine disorder management and the adoption of advanced, patient-friendly drug formulations. This sector is shaped by increasing prevalence of conditions such as acromegaly, Cushing's disease, and neuroendocrine tumors, as well as by the continual evolution of technology-driven delivery solutions. The competitive landscape features a blend of established pharmaceutical leaders and innovative biotechs pursuing next-generation therapies and combination regimens, with value-based care principles influencing market access and payer engagement strategies.

Scope & Segmentation

This report provides a comprehensive examination of the long-acting somatostatin analogue market by product, indication, administration, distribution, patient demographic, and region.

  • Product Type: Covers lanreotide autogel, octreotide LAR, and pasireotide LAR, each associated with differentiated release profiles and patient outcomes.
  • Indication: Evaluates application in acromegaly, Cushing's disease, and neuroendocrine tumors, including gastroenteropancreatic and pulmonary subtypes.
  • Route of Administration: Analyzes deep subcutaneous versus intramuscular injection strategies, linked to patient experience and care setting preferences.
  • Distribution Channel: Considers hospital pharmacies, mail order, and retail outlets, correlating distribution with access, inventory, and reimbursement models.
  • Patient Age Group: Distinguishes between adult and pediatric segments, recognizing dosage frequency and unique support needs.
  • Geographic Coverage: Explores key trends across the Americas (including the United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (UK, Germany, France, Russia, Italy, Spain, United Arab Emirates, Saudi Arabia, South Africa, Denmark, Netherlands, Qatar, Finland, Sweden, Nigeria, Egypt, Turkey, Israel, Norway, Poland, Switzerland), and Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam, Taiwan).
  • Company Landscape: Analyzes leading participants such as Novartis AG and Ipsen S.A. for market presence, partnerships, and innovation strategies.

Key Takeaways for Decision-Makers

  • Advances in molecular engineering and digital health are driving paradigm shifts, enabling precise release and biomarker-guided treatment regimes for targeted patient subpopulations.
  • Introduction of formulations like lanreotide autogel and octreotide LAR has enhanced personalized therapy and quality of life, while expanding clinical adoption across diverse disease indications.
  • Value-based care models are influencing product adoption, with real-world evidence and outcome-based contracts incentivizing positive clinical and economic results.
  • Competitive pressures from biosimilars and next-generation analogues are accelerating market innovation and collaborative licensing agreements, optimizing portfolios for cross-regional reach.
  • Segmentation analysis reveals that administration route, patient age, and tumor subtype complexity all impact product selection, therapy adherence, and distribution patterns.
  • Global healthcare reforms and rising public-private investment in Asia-Pacific and EMEA are fostering new growth opportunities amid regulatory and logistical challenges.

Tariff Impact: 2025 US Policy Changes

The 2025 US tariff reforms have significantly affected cost structures and supply chain resilience for somatostatin analogue manufacturing, particularly for products dependent on imported active pharmaceutical ingredients. Manufacturers responded with procurement diversification and onshore production strategies to mitigate inflationary pressure, while renegotiations with raw material partners and healthcare payers promote cost transparency and continuity of product availability. Furthermore, R&D investment decisions increasingly reflect tariff-associated risks, encouraging footprint consolidation and production agility.

Methodology & Data Sources

The analysis is grounded in comprehensive secondary research drawing on peer-reviewed publications, clinical registries, and regulatory filings, supplemented by in-depth interviews with endocrinologists, hospital pharmacists, and industry executives. Triangulation processes, cross-referencing with financial data, and regional workshops support robust, unbiased insights while ensuring data accuracy on long-acting somatostatin analogues.

Why This Report Matters to Senior Leaders

  • Identifies actionable opportunities for portfolio optimization, global market expansion, and risk mitigation within the somatostatin analogue landscape.
  • Equips decision-makers with granular segmentation insights and forward-looking perspectives on biosimilar competition, reimbursement trends, and digital integration strategies.

Conclusion

The evolving market for long-acting somatostatin analogues requires agile, evidence-based strategies to address regulatory, clinical, and operational complexities. Senior leaders leveraging these insights can enhance market positioning and maintain sustainable growth within this specialized sector.



This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Increasing adoption of long-acting somatostatin analogues in pediatric neuroendocrine tumor management
5.2. Development of novel oral octreotide formulations to improve patient adherence and outcomes
5.3. Advancements in sustained-release delivery systems for pasireotide in acromegaly treatment
5.4. Emerging biosimilar approvals disrupting the long-acting somatostatin analogue pricing landscape
5.5. Integration of real-world evidence to tailor long-acting somatostatin analogue dosing strategies
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Long-acting Somatostatin Analogues Market, by Product Type
8.1. Introduction
8.2. Lanreotide Autogel
8.3. Octreotide LAR
8.4. Pasireotide LAR
9. Long-acting Somatostatin Analogues Market, by Indication
9.1. Introduction
9.2. Acromegaly
9.3. Cushing's Disease
9.4. Neuroendocrine Tumors
9.4.1. Gastroenteropancreatic NETs
9.4.2. Pulmonary NETs
10. Long-acting Somatostatin Analogues Market, by Route Of Administration
10.1. Introduction
10.2. Deep Subcutaneous Injection
10.3. Intramuscular Injection
11. Long-acting Somatostatin Analogues Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacies
11.3. Mail Order Pharmacies
11.4. Retail Pharmacies
12. Long-acting Somatostatin Analogues Market, by Patient Age Group
12.1. Introduction
12.2. Adult
12.3. Pediatric
13. Americas Long-acting Somatostatin Analogues Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Long-acting Somatostatin Analogues Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Long-acting Somatostatin Analogues Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Novartis AG
16.3.2. Ipsen S.A.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. LONG-ACTING SOMATOSTATIN ANALOGUES MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2030 (%)
FIGURE 14. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. LONG-ACTING SOMATOSTATIN ANALOGUES MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. LONG-ACTING SOMATOSTATIN ANALOGUES MARKET: RESEARCHAI
FIGURE 26. LONG-ACTING SOMATOSTATIN ANALOGUES MARKET: RESEARCHSTATISTICS
FIGURE 27. LONG-ACTING SOMATOSTATIN ANALOGUES MARKET: RESEARCHCONTACTS
FIGURE 28. LONG-ACTING SOMATOSTATIN ANALOGUES MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY LANREOTIDE AUTOGEL, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY LANREOTIDE AUTOGEL, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY OCTREOTIDE LAR, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY OCTREOTIDE LAR, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PASIREOTIDE LAR, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PASIREOTIDE LAR, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ACROMEGALY, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ACROMEGALY, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY CUSHING'S DISEASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY CUSHING'S DISEASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY GASTROENTEROPANCREATIC NETS, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY GASTROENTEROPANCREATIC NETS, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PULMONARY NETS, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PULMONARY NETS, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DEEP SUBCUTANEOUS INJECTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DEEP SUBCUTANEOUS INJECTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INTRAMUSCULAR INJECTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INTRAMUSCULAR INJECTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY MAIL ORDER PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY MAIL ORDER PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ADULT, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. AMERICAS LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 52. AMERICAS LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 53. AMERICAS LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 54. AMERICAS LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 55. AMERICAS LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, 2018-2024 (USD MILLION)
TABLE 56. AMERICAS LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, 2025-2030 (USD MILLION)
TABLE 57. AMERICAS LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 58. AMERICAS LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 59. AMERICAS LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 60. AMERICAS LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 61. AMERICAS LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 62. AMERICAS LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 63. AMERICAS LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 64. AMERICAS LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 65. UNITED STATES LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 66. UNITED STATES LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 67. UNITED STATES LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 68. UNITED STATES LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 69. UNITED STATES LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, 2018-2024 (USD MILLION)
TABLE 70. UNITED STATES LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, 2025-2030 (USD MILLION)
TABLE 71. UNITED STATES LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 72. UNITED STATES LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 73. UNITED STATES LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 74. UNITED STATES LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 75. UNITED STATES LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 76. UNITED STATES LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 77. UNITED STATES LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 78. UNITED STATES LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 79. CANADA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 80. CANADA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 81. CANADA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 82. CANADA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 83. CANADA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, 2018-2024 (USD MILLION)
TABLE 84. CANADA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, 2025-2030 (USD MILLION)
TABLE 85. CANADA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 86. CANADA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 87. CANADA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 88. CANADA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 89. CANADA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 90. CANADA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 91. MEXICO LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 92. MEXICO LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 93. MEXICO LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 94. MEXICO LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 95. MEXICO LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, 2018-2024 (USD MILLION)
TABLE 96. MEXICO LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, 2025-2030 (USD MILLION)
TABLE 97. MEXICO LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 98. MEXICO LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 99. MEXICO LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 100. MEXICO LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 101. MEXICO LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 102. MEXICO LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 103. BRAZIL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 104. BRAZIL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 105. BRAZIL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 106. BRAZIL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 107. BRAZIL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, 2018-2024 (USD MILLION)
TABLE 108. BRAZIL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, 2025-2030 (USD MILLION)
TABLE 109. BRAZIL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 110. BRAZIL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 111. BRAZIL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 112. BRAZIL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 113. BRAZIL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 114. BRAZIL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 115. ARGENTINA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 116. ARGENTINA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 117. ARGENTINA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 118. ARGENTINA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 119. ARGENTINA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, 2018-2024 (USD MILLION)
TABLE 120. ARGENTINA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, 2025-2030 (USD MILLION)
TABLE 121. ARGENTINA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 122. ARGENTINA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 123. ARGENTINA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 124. ARGENTINA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 125. ARGENTINA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 126. ARGENTINA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 127. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 128. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 129. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 130. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 131. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, 2018-2024 (USD MILLION)
TABLE 132. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, 2025-2030 (USD MILLION)
TABLE 133. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 134. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 135. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 136. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 137. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 138. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 139. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 140. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 141. UNITED KINGDOM LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 142. UNITED KINGDOM LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 143. UNITED KINGDOM LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 144. UNITED KINGDOM LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 145. UNITED KINGDOM LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, 2018-2024 (USD MILLION)
TABLE 146. UNITED KINGDOM LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, 2025-2030 (USD MILLION)
TABLE 147. UNITED KINGDOM LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 148. UNITED KINGDOM LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 149. UNITED KINGDOM LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 150. UNITED KINGDOM LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 151. UNITED KINGDOM LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 152. UNITED KINGDOM LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 153. GERMANY LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 154. GERMANY LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 155. GERMANY LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 156. GERMANY LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 157. GERMANY LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, 2018-2024 (USD MILLION)
TABLE 158. GERMANY LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, 2025-2030 (USD MILLION)
TABLE 159. GERMANY LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 160. GERMANY LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 161. GERMANY LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 162. GERMANY LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 163. GERMANY LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 164. GERMANY LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 165. FRANCE LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 166. FRANCE LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 167. FRANCE LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 168. FRANCE LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 169. FRANCE LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, 2018-2024 (USD MILLION)
TABLE 170. FRANCE LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, 2025-2030 (USD MILLION)
TABLE 171. FRANCE LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 172. FRANCE LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 173. FRANCE LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 174. FRANCE LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 175. FRANCE LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 176. FRANCE LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 177. RUSSIA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 178. RUSSIA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 179. RUSSIA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 180. RUSSIA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 181. RUSSIA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, 2018-2024 (USD MILLION)
TABLE 182. RUSSIA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, 2025-2030 (USD MILLION)
TABLE 183. RUSSIA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 184. RUSSIA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 185. RUSSIA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 186. RUSSIA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 187. RUSSIA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 188. RUSSIA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 189. ITALY LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 190. ITALY LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 191. ITALY LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 192. ITALY LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 193. ITALY LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, 2018-2024 (USD MILLION)
TABLE 194. ITALY LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, 2025-2030 (USD MILLION)
TABLE 195. ITALY LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 196. ITALY LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 197. ITALY LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 198. ITALY LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 199. ITALY LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 200. ITALY LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 201. SPAIN LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 202. SPAIN LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 203. SPAIN LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 204. SPAIN LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 205. SPAIN LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, 2018-2024 (USD MILLION)
TABLE 206. SPAIN LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, 2025-2030 (USD MILLION)
TABLE 207. SPAIN LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 208. SPAIN LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 209. SPAIN LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 210. SPAIN LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 211. SPAIN LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 212. SPAIN LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 213. UNITED ARAB EMIRATES LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 214. UNITED ARAB EMIRATES LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 215. UNITED ARAB EMIRATES LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 216. UNITED ARAB EMIRATES LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 217. UNITED ARAB EMIRATES LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, 2018-2024 (USD MILLION)
TABLE 218. UNITED ARAB EMIRATES LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, 2025-2030 (USD MILLION)
TABLE 219. UNITED ARAB EMIRATES LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 220. UNITED ARAB EMIRATES LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 221. UNITED ARAB EMIRATES LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 222. UNITED ARAB EMIRATES LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 223. UNITED ARAB EMIRATES LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 224. UNITED ARAB EMIRATES LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 225. SAUDI ARABIA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 226. SAUDI ARABIA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 227. SAUDI ARABIA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 228. SAUDI ARABIA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 229. SAUDI ARABIA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, 2018-2024 (USD MILLION)
TABLE 230. SAUDI ARABIA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, 2025-2030 (USD MILLION)
TABLE 231. SAUDI ARABIA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 232. SAUDI ARABIA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 233. SAUDI ARABIA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 234. SAUDI ARABIA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 235. SAUDI ARABIA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 236. SAUDI ARABIA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 237. SOUTH AFRICA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 238. SOUTH AFRICA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 239. SOUTH AFRICA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 240. SOUTH AFRICA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 241. SOUTH AFRICA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, 2018-2024 (USD MILLION)
TABLE 242. SOUTH AFRICA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, 2025-2030 (USD MILLION)
TABLE 243. SOUTH AFRICA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 244. SOUTH AFRICA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 245. SOUTH AFRICA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 246. SOUTH AFRICA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 247. SOUTH AFRICA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 248. SOUTH AFRICA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 249. DENMARK LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 250. DENMARK LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 251. DENMARK LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 252. DENMARK LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 253. DENMARK LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, 2018-2024 (USD MILLION)
TABLE 254. DENMARK LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, 2025-2030 (USD MILLION)
TABLE 255. DENMARK LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 256. DENMARK LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 257. DENMARK LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 258. DENMARK LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 259. DENMARK LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 260. DENMARK LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 261. NETHERLANDS LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 262. NETHERLANDS LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 263. NETHERLANDS LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 264. NETHERLANDS LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 265. NETHERLANDS LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, 2018-2024 (USD MILLION)
TABLE 266. NETHERLANDS LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, 2025-2030 (USD MILLION)
TABLE 267. NETHERLANDS LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 268. NETHERLANDS LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 269. NETHERLANDS LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 270. NETHERLANDS LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 271. NETHERLANDS LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 272. NETHERLANDS LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 273. QATAR LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 274. QATAR LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 275. QATAR LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 276. QATAR LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 277. QATAR LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, 2018-2024 (USD MILLION)
TABLE 278. QATAR LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, 2025-2030 (USD MILLION)
TABLE 279. QATAR LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 280. QATAR LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 281. QATAR LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 282. QATAR LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 283. QATAR LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 284. QATAR LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Long-acting Somatostatin Analogues market report include:
  • Novartis AG
  • Ipsen S.A.

Related Topics

Related Reports

Somatostatin Analogs Market Report 2025 - Product Image

Somatostatin Analogs Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Somatostatin Analogs Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type - Product Image

Somatostatin Analogs Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type

  • Report
  • 82 Pages
  • Global
From
Somatostatin Analogs Market - Global Forecast 2025-2032 - Product Image

Somatostatin Analogs Market - Global Forecast 2025-2032

  • Report
  • 188 Pages
  • Global
From
Somatostatin Analogs Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034 - Product Image

Somatostatin Analogs Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034

  • Report
  • 130 Pages
  • Global
From
Somatostatin Analogs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Somatostatin Analogs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 180 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.